Median Technologies : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31st, 2021

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris: ALMDT):

(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI France and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME), is listed on the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005859/en/

Median Technologies
Emmanuelle Leygues
Head of Corporate and Marketing Communications
+33 6 10 93 58 88
[email protected]

Press - ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
[email protected]

Investors - ACTIFIN
Ghislaine Gasparetto
+33 1 56 88 11 11
[email protected]

Source: Median Technologies

You May Also Be Interested In

• SEGRO plc Trading Update
• Vallourec progresses its holistic balance sheet refinancing with successful pricing of its 2032 Senior Notes offering
• Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity